ESC Congress 2022 (Photo by Kyle LaHucik)

#ESC22: BMS-J&J’s mil­vex­i­an miss­es com­pos­ite end­point, but duo to push drug for­ward with signs of sec­ondary stroke pre­ven­tion and ‘flat bleed­ing curve’

BARCELONA — Bris­tol My­ers Squibb and J&J’s Janssen look to move for­ward with a Phase III of their fac­tor XIa drug in pre­vent­ing sec­ondary stroke …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.